Meeting Banner
Abstract #2395

The measurement of the characteristics of the metabolic syndrome and the effect of a targeted treatment of rosiglitazone

Ernst Suidgeest 1 , Bigit Den Adel 1,2 , Jos W.A. Van der Hoorn 3 , Rob E Poelmann 4 , and Louise Van der Weerd 1,5

1 Radiology, LUMC, Leiden, Netherlands, 2 Anatomy, LUMC, Netherlands, 3 Metabolic Health Research, TNO, Leiden, Netherlands, 4 Anatomy, LUMC, Leiden, Netherlands, 5 Human Genetics, LUMC, Netherlands

The objectives of this study were: 1. to establish whether rosiglitazone administration causes cardiac dysfunction in a mouse model. 2. to establish whether liposome-encapsulation reduces these side effects, if present, and 3. to investigate whether liposomal delivery of rosiglitazone preserves the therapeutic response compared to standard rosiglitazone. This study shows that MRI is a tool that can be used to assess the diverse aspects of metabolic syndrome. We showed that rosiglitazone at a standard clinical dose induces dilated cardiomyopathy and weight gain in the LDLr-/- mouse model. Micelle encapsulation of rosiglitazone significantly improves these unwanted side effects.

This abstract and the presentation materials are available to members only; a login is required.

Join Here